The monograph offers flexibility in how manufacturers demonstrate that a tablet will release its active substance appropriately. For rapidly dissolving products containing highly soluble active substances, a as described in the monograph may be sufficient.
Mastering this revised framework is the first step toward "better" compliance. The following sections will guide you through the critical tests and how to approach them strategically. european pharmacopoeia ph eur monograph tablets 0478 better
Using advanced superdisintegrants (such as cross-linked polyvinylpyrrolidone or sodium starch glycolate) creates predictable release kinetics. This minimizes the time to reach therapeutic plasma concentrations and reduces patient-to-patient variability. Superior Mechanical Strength and Cohesiveness The following sections will guide you through the
The updated 0478 monograph requires manufacturers to prove that these divisions are accurate during product development and validation, preventing issues with uneven dosage distribution. modern analytical expectations (especially for dissolution)
Ph. Eur. monograph 0478 for tablets is foundational for ensuring tablet quality across markets. Updating the monograph to incorporate clearer decision rules, modern analytical expectations (especially for dissolution), risk-based approaches, and stronger guidance for special tablet types (ODT, chewable, coated) would make it more practical and aligned with current pharmaceutical science. Manufacturers should adopt a QbD mindset, implement validated, discriminatory methods, and use robust sampling and statistical controls to meet and exceed monograph expectations.